This insight brief highlights recent advances in Alzheimer’s disease (AD) research and the critical role of innovative laboratory solutions in accelerating clinical development. While AD remains an area of significant unmet need, progress has been marked by the FDA approvals of disease-modifying therapies such as lecanemab and donanemab, which target underlying disease biology. Alongside therapeutic advances, substantial innovation has occurred in laboratory testing, including biomarkers that support earlier diagnosis, patient stratification, and monitoring of disease progression. The brief emphasizes how advanced bioanalytical methods, standardized assays, and integrated lab strategies improve trial efficiency, data quality, and decision-making. By aligning laboratory innovation with evol

Join for free to read